NEOG
Neogen CorpPrice & Indicators
TL;DR.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | $48.2M | Q3 FY2026 | — |
|
|
|||
| Adjusted EBITDA Margin non-GAAP | 22.8% | Q3 FY2026 | — |
|
|
|||
| Core revenue growth non-GAAP | 0.1% | Q3 FY2026 | — |
| Free cash flow | $11.1M | Q3 FY2026 | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
NEOG
this stock
Neogen Corp
|
$2.10B | +38.1% | -3.2% | — | 4.8% |
|
ABT
Abbott Laboratories
|
$160.44B | -26.1% | +5.7% | 25.8 | 1.3% |
|
SYK
Stryker Corp
|
$127.06B | -5.4% | +11.2% | 38.4 | 1.8% |
|
MDT
Medtronic plc
|
$106.97B | -12.3% | +8.4% | 22.4 | 1.5% |
|
BSX
Boston Scientific Corp
|
$66.37B | -53.2% | +5.5% | 18.7 | 1.9% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| NEOG | +1.5% | +4.3% | +4.3% | +7.3% | +38.1% |
| SPY | -0.3% | +1.6% | +8.3% | +0.3% | +9.9% |
| vs SPY | +1.8% | +2.8% | -4.0% | +7.0% | +28.2% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.